Physician profile
Teon Taylor
NPI 1487287116
$2,080.29
in general payments reported to CMS, 2019-2025
25 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.73 · 2022: $426 · 2023: $1,080 · 2024: $324 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $266.53 | 2023-2024 | Breztri, Farxiga |
| Novo Nordisk INC | $242.66 | 2022-2024 | Wegovy, Rybelsus, Ozempic |
| Paratek Pharmaceuticals, INC. | $227.14 | 2022-2023 | Nuzyra |
| Indivior INC. | $176.11 | 2024-2025 | Sublocade |
| Abbvie INC. | $163.42 | 2023-2024 | |
| Lilly USA, LLC | $110.29 | 2022-2024 | Emgality, Reyvow, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $91.23 | 2022-2023 | |
| Glaxosmithkline, LLC. | $85.23 | 2023-2024 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $75.01 | 2022-2023 | Trintellix |
| Dexcom, INC. | $65.80 | 2023-2024 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $65.06 | 2023-2024 | Austedo Xr, Ajovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.67 | 2023-2024 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $54.92 | 2022-2023 | Otezla, Repatha |
| Boston Scientific Corporation | $48.97 | 2025 | Wavewriter Alpha Prime 16 |
| Novartis Pharmaceuticals Corporation | $47.89 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $47.79 | 2023-2024 | |
| Genentech USA, INC. | $47.73 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.65 | 2023 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $31.54 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $30.82 | 2023 | Seglentis |
| Exact Sciences Corporation | $24.07 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $23.44 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $23.00 | 2023 | Rexulti |
| Azurity Pharmaceuticals, INC. | $14.53 | 2023 | Horizant |
| Ibsa Pharma INC. | $13.79 | 2024 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teon Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.